Healthcare · Pharmaceuticals: Major

AbbVie, Inc.

NYSEABBV ISINUS00287Y1091 SEC CIK0001551152 Listed on NYSE · USD

$297.55 +2.57 (+0.87%) Pre-market $298.96 (+1.35%) ≈ ₹27,926 a share

Open chart

Price, last 12 months+34.60% in a year

Key numbers

Market value: $525.95B
P/E (TTM): 51.2
Forward P/E: 19.5
EPS (TTM): $5.81
Dividend yield: 2.45%
Beta: 0.19
Day range: $295.37 – $300.42
52-week range: $190.75 – $302.93
Volume: 618,149
10-day avg volume: $5.95M
Revenue (TTM): $66.01B
EBITDA (TTM): $31.57B
Gross margin: 73.7%
Net margin: 15.7%
Return on equity: 15,221.8%
Debt / equity: -1,765.3%
Price / sales: 7.97
Shares out: 1.77B

52W low52W high

Quarterly results

Results for each quarter

Last 12 quarters from 10-Q and 10-K filings with the US SEC. Q4 = full year minus the first three quarters. Hover a bar to see the number.

Revenue and net income

$14.30B$3.20B$822.00M

Dec 23

$12.31B$2.80B$1.37B

Mar 24

$14.46B$4.00B$1.37B

Jun 24

$14.46B$3.83B$1.56B

Sep 24

$15.10B$-1.49B$-22.00M

Dec 24

$13.34B$3.73B$1.29B

Mar 25

$15.42B$4.89B$938.00M

Jun 25

$15.78B$1.90B$186.00M

Sep 25

$16.62B$4.54B$1.82B

Dec 25

$15.00B$3.99B$695.00M

Mar 26

$16.99B$6.43B$3.61B

Jun 26

$17.40B$6.27B$4.22B

Sep 26

Revenue · QoQ (vs last quarter)

—-14%+17%0.0%+4.4%-12%+16%+2.3%+5.3%-9.7%+13%+2.4%

Revenue · YoY (vs a year ago)

————+5.6%+8.4%+6.6%+9.1%+10%+12%+10%+10%

Net income · QoQ (vs last quarter)

—+67%+0.1%+14%-101%+5,945%-27%-80%+876%-62%+420%+17%

Net income · YoY (vs a year ago)

————-103%-6.1%-32%-88%+8,355%-46%+285%+2,168%

RevenueOperating incomeNet incomeLine = trend

US$	Dec 23	Mar 24	Jun 24	Sep 24	Dec 24	Mar 25	Jun 25	Sep 25	Dec 25	Mar 26	Jun 26	Sep 26
Revenue	$14.30B	$12.31B	$14.46B	$14.46B	$15.10B	$13.34B	$15.42B	$15.78B	$16.62B	$15.00B	$16.99B	$17.40B
Cost of revenue	$5.70B	$4.09B	$4.20B	$4.21B	$4.40B	$4.00B	$4.35B	$5.30B	$4.55B	$4.22B	$4.29B	$4.29B
Gross profit	$8.60B	$8.22B	$10.26B	$10.25B	$10.71B	$9.34B	$11.08B	$10.47B	$12.07B	$10.78B	$12.70B	$13.12B
Gross margin	60.1%	66.7%	70.9%	70.9%	70.9%	70.0%	71.8%	66.4%	72.6%	71.9%	74.7%	75.4%
Selling, general & admin	$3.19B	$3.32B	$3.38B	$4.21B	$3.86B	$3.29B	$3.25B	$3.57B	$3.90B	$3.58B	$3.63B	$4.09B
Operating income	$3.20B	$2.80B	$4.00B	$3.83B	$-1.49B	$3.73B	$4.89B	$1.90B	$4.54B	$3.99B	$6.43B	$6.27B
Operating margin	22.3%	22.7%	27.6%	26.5%	-9.9%	28.0%	31.7%	12.1%	27.3%	26.6%	37.9%	36.0%
Interest expense	$564.00M	$660.00M	$726.00M	$720.00M	$702.00M	$700.00M	$740.00M	$739.00M	$714.00M	$717.00M	$746.00M	$802.00M
Pre-tax income	$1.21B	$1.76B	$2.15B	$2.08B	$-2.27B	$1.66B	$1.55B	$714.00M	$2.67B	$1.04B	$4.28B	$4.83B
Income tax	$388.00M	$383.00M	$773.00M	$520.00M	$-2.25B	$372.00M	$613.00M	$526.00M	$853.00M	$342.00M	$662.00M	$609.00M
Net income	$822.00M	$1.37B	$1.37B	$1.56B	$-22.00M	$1.29B	$938.00M	$186.00M	$1.82B	$695.00M	$3.61B	$4.22B
Net margin	5.7%	11.1%	9.5%	10.8%	-0.1%	9.6%	6.1%	1.2%	10.9%	4.6%	21.3%	24.2%
EPS (diluted)	$0.46	$0.77	$0.77	$0.88	$-0.02	$0.72	$0.52	$0.10	$1.02	$0.39	$2.03	$2.37

Income statement

Results for each year

8 fiscal years from the company's 10-K filings with the US SEC.

Revenue, gross profit and net income

$32.75B$25.04B$5.69B

FY18

$33.27B$25.83B$7.88B

FY19

$45.80B$30.42B$4.62B

FY20

$56.20B$38.75B$11.54B

FY21

$58.05B$40.64B$11.84B

FY22

$54.32B$33.90B$4.86B

FY23

$56.33B$39.43B$4.28B

FY24

$61.16B$42.96B$4.23B

FY25

Revenue · YoY (vs a year ago)

—+1.6%+38%+23%+3.3%-6.4%+3.7%+8.6%

Net income · YoY (vs a year ago)

—+39%-41%+150%+2.5%-59%-12%-1.2%

RevenueGross profitNet incomeLine = trend

$3.66

FY18

$5.28

FY19

$2.72

FY20

$6.45

FY21

$6.63

FY22

$2.72

FY23

$2.39

FY24

$2.36

FY25

EPS (diluted) · YoY (vs a year ago)

—+44%-48%+137%+2.8%-59%-12%-1.3%

EPS (diluted)Line = trend

US$	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Revenue	$32.75B	$33.27B	$45.80B	$56.20B	$58.05B	$54.32B	$56.33B	$61.16B
Revenue growth	—	1.6%	37.7%	22.7%	3.3%	-6.4%	3.7%	8.6%
Cost of revenue	$7.72B	$7.44B	$15.39B	$17.45B	$17.41B	$20.42B	$16.90B	$18.20B
Gross profit	$25.04B	$25.83B	$30.42B	$38.75B	$40.64B	$33.90B	$39.43B	$42.96B
Gross margin	76.4%	77.6%	66.4%	69.0%	70.0%	62.4%	70.0%	70.2%
Selling, general & admin	$7.40B	$6.94B	$11.30B	$12.35B	$15.26B	$12.87B	$14.75B	$14.01B
Operating income	$6.38B	$12.98B	$11.36B	$17.92B	$18.12B	$12.76B	$9.14B	$15.08B
Operating margin	19.5%	39.0%	24.8%	31.9%	31.2%	23.5%	16.2%	24.6%
Interest expense	$1.35B	$1.78B	$2.45B	$2.42B	$2.23B	$2.22B	$2.81B	$2.89B
Pre-tax income	$5.20B	$8.43B	$3.40B	$12.99B	$13.48B	$6.25B	$3.72B	$6.60B
Income tax	$-490.00M	$544.00M	$-1.22B	$1.44B	$1.63B	$1.38B	$-570.00M	$2.36B
Tax rate	-9.4%	6.5%	-36.0%	11.1%	12.1%	22.0%	-15.3%	35.8%
Net income	$5.69B	$7.88B	$4.62B	$11.54B	$11.84B	$4.86B	$4.28B	$4.23B
Net margin	17.4%	23.7%	10.1%	20.5%	20.4%	9.0%	7.6%	6.9%
EPS (diluted)	$3.66	$5.28	$2.72	$6.45	$6.63	$2.72	$2.39	$2.36

Balance sheet

Assets and debt

At each fiscal year end.

Equity, debt and cash

$-8.45B$8.06B

FY18

$-8.17B$67.23B$39.92B

FY19

$13.08B$84.95B$8.48B

FY20

$15.41B$75.96B$9.83B

FY21

$17.25B$63.13B$9.23B

FY22

$10.36B$59.25B$12.82B

FY23

$3.33B$66.84B$5.56B

FY24

$-3.27B$64.50B$5.26B

FY25

Shareholders' equity · YoY (vs a year ago)

—+3.2%+260%+18%+12%-40%-68%-198%

Shareholders' equityTotal debtCash + short-term investmentsLine = trend

US$	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Cash & equivalents	$7.29B	$39.92B	$8.45B	$9.75B	$9.20B	$12.81B	$5.52B	$5.23B
Short-term investments	$772.00M	$0	$30.00M	$84.00M	$28.00M	$2.00M	$31.00M	$28.00M
Current assets	$16.95B	$49.52B	$24.17B	$27.93B	$28.46B	$33.00B	$25.58B	$29.06B
Total assets	$59.35B	$89.12B	$150.57B	$146.53B	$138.81B	$134.71B	$135.16B	$133.96B
Current liabilities	$17.24B	$15.59B	$28.66B	$35.19B	$29.54B	$37.84B	$38.75B	$43.29B
Long-term debt	—	$67.23B	$84.95B	$75.96B	$63.13B	$59.25B	$66.84B	$64.50B
Total debt	—	$67.23B	$84.95B	$75.96B	$63.13B	$59.25B	$66.84B	$64.50B
Shareholders' equity	$-8.45B	$-8.17B	$13.08B	$15.41B	$17.25B	$10.36B	$3.33B	$-3.27B
Current ratio	0.98	3.18	0.84	0.79	0.96	0.87	0.66	0.67
Debt / equity	—	—	6.50	4.93	3.66	5.72	20.10	—
Return on equity	—	—	35.3%	74.9%	68.6%	46.9%	128.7%	—

Cash flow

Cash coming in and going out

Free cash flow = cash from operations minus capital spending. Shareholder returns = dividends + buybacks.

Free cash flow and shareholder returns

$13.43B$12.79B$17.59B

FY18

$13.32B$12.77B$7.00B

FY19

$17.59B$16.79B$8.69B

FY20

$22.78B$21.99B$10.20B

FY21

$24.94B$24.25B$11.53B

FY22

$22.84B$22.06B$12.51B

FY23

$18.81B$17.83B$12.73B

FY24

$19.03B$17.82B$12.64B

FY25

Operating cash flow · YoY (vs a year ago)

—-0.8%+32%+30%+9.5%-8.4%-18%+1.2%

Free cash flow · YoY (vs a year ago)

—-0.1%+31%+31%+10%-9.0%-19%-0.1%

Operating cash flowFree cash flowDividends + buybacksLine = trend

US$	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Cash from operations	$13.43B	$13.32B	$17.59B	$22.78B	$24.94B	$22.84B	$18.81B	$19.03B
Capital spending	$-638.00M	$-552.00M	$-798.00M	$-787.00M	$-695.00M	$-777.00M	$-974.00M	$-1.21B
Free cash flow	$12.79B	$12.77B	$16.79B	$21.99B	$24.25B	$22.06B	$17.83B	$17.82B
FCF margin	39.0%	38.4%	36.7%	39.1%	41.8%	40.6%	31.7%	29.1%
Stock-based pay	$421.00M	$430.00M	$753.00M	$692.00M	$671.00M	$747.00M	$911.00M	$955.00M
Cash from investing	$-1.01B	$596.00M	$-37.56B	$-2.34B	$-623.00M	$-2.01B	$-20.82B	$-6.64B
Cash from financing	$-14.40B	$18.71B	$-11.50B	$-19.04B	$-24.80B	$-17.22B	$-5.21B	$-12.72B
Dividends paid	$-5.58B	$-6.37B	$-7.72B	$-9.26B	$-10.04B	$-10.54B	$-11.03B	$-11.66B
Share buybacks	$-12.01B	$-629.00M	$-978.00M	$-934.00M	$-1.49B	$-1.97B	$-1.71B	$-980.00M

About

About AbbVie, Inc.

AbbVie Inc., also known as AbbVie, is an American pharmaceutical company headquartered in North Chicago, Illinois. AbbVie produces drugs to treat a wide range of medical issues.

From Wikipedia (CC BY-SA 4.0).

Company details

Company name: AbbVie, Inc.
Ticker: ABBV
Exchange: NYSE
ISIN: US00287Y1091
SEC CIK: 0001551152
Sector: Healthcare
Industry: Pharmaceuticals: Major
SEC industry (SIC): Pharmaceutical Preparations (2834)
Incorporated in: Delaware
Financial year ends: 31 December
Filer type: Large accelerated filer
Latest annual report (10-K): 20 Feb 2026
CEO: Robert A. Michael
Chair: Robert A. Michael
Headquarters: North Chicago
Address: 1 North Waukegan Road, North Chicago, Il 60064
Founded: 2012
Employees: 57,000
Trades in: US dollars (USD)
Website: abbvie.com

News

Peers

Others in Healthcare

Quotes from CNBC (may be delayed), financials from SEC EDGAR, profile from global-stock-logos (MIT). Information only, not investment advice.

India, Wall Street, crypto and commodities, live.

Every product, one clear workflow.

Built from data, on the record.

A clearer view of the markets.

Calculators and tools that show the maths.

Read the numbers, not the noise.

AbbVie, Inc.

Key numbers

Quarterly results

Revenue and net income

Income statement

Revenue, gross profit and net income

Balance sheet

Equity, debt and cash

Cash flow

Free cash flow and shareholder returns

About

Company details

News

Peers